Phase II, Open Label Adaptive Design Dose Finding Study to Investigate Effect of Synthetic PreImplantation Factor (sPIF) in Patients With High Panel Reactive Antibodies
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 10 Jan 2019
At a glance
- Drugs Preimplantation factor (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 31 Dec 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2020.
- 31 Dec 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
- 31 Dec 2018 Planned initiation date changed from 1 Oct 2018 to 1 Feb 2019.